. The islet microvasculature is critical for efficient insulin delivery to the bloodstream. Mice with reduced islet vasculature deliver less secreted insulin from islets to the bloodstream in vivo and have reduced glucose tolerance (14, 32) . The microvasculature is also important for insulin action. In muscle, the process of delivering insulin from the bloodstream across the endothelial cell layer into the interstitium appears to be a rate-limiting step for insulin action and may contribute to insulin resistance (6, 18) . Uptake of FITC-insulin by rat skeletal muscle endothelial cells occurs within 10 min of intravenous injection, but the FITCinsulin remains concentrated in endothelial cells for up to 60 min after injection (50) . The process of transendothelial insulin transport requires the expression of caveolin-1, suggesting a caveloaemediated mechanism (51) . In contrast, there appears to be no time delay between the appearance of insulin in lymph and activation of the insulin receptor in myocytes (39). Accordingly, after insulin is directly injected into the muscle interstitium, there is a strong correlation between the interstitial insulin concentration and local glucose uptake (17) . Thus, once insulin enters the interstitial space, receptor binding, signaling, and stimulation of glucose uptake are essentially instantaneous.
The liver displays a unique sinusoidal structure, characterized by gaps between endothelial cells, large fenestrae, and lack of a well-formed basement membrane. Fenestrae occupy 10% of the sinusoidal surface and are organized into clusters, termed "sieve plates." They connect the sinusoidal lumen directly to the space of Disse, which lines the basolateral surface of the endothelium and interacts with hepatocyte cell membranes and microvilli (4) . These fenestrated discontinuous hepatic sinusoids are highly permeable and allow particles smaller than 100 nm to freely diffuse into the space of Disse (34) . Therefore, unlike muscle, the liver vasculature is considered not to be rate limiting for nutrient transport under normal circumstances.
However, hepatic nutrient transport out of the bloodstream and diffusion through the space of Disse is hindered during certain pathological conditions. "Capillarization" is the process by which hepatic sinusoids undergo morphological changes that include sinusoidal defenestration, the development of basement membrane, and excessive distortion of the space of Disse due to extracellular matrix (ECM) deposition (34) . These ultrastructural changes result from the activation of liver pericytes, also termed hepatic stellate cells (HSCs) (45) , and PDGF-B signaling can induce HSC activation (20) . Capillarization-like phenotypes have been noted in fibrosis (34) , aging (34) , and type 1 diabetes (8, 9, 30, 33). Defenestration and perisinusoidal fibrosis are also present in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, the two most common manifestations of hepatic insulin resistance (22) . Capillarization can impede the delivery of nutrients and small molecules to hepatocytes (15, 34) , although hepatic insulin delivery has not been examined under these conditions. Few studies have examined the effects of PDGF-B signaling and pericytes in insulin action. PDGF-B signaling can induce glucose transporter 4 translocation in both cultured adipocytes (52) and mouse skeletal muscle (55) , but only under conditions of PDGFR␤ overexpression. The effect of PDGF-B on insulin action in hepatocytes has not been examined, although the low endogenous expression of PDGFR␤ in these cells suggests that PDGF-B would have little direct effect on hepatocyte function (46) but rather through modulation of pericytes and the vasculature.
One pathway potentially modulated by PDGF-B is the maintenance of vascular barrier function. Mice with reduced pericyte coverage of the vasculature display widespread and often lethal vascular hemorrhage and edema (27, 28, 35, 36, 47) . Loss of pericyte retention on blood vessels in tumors leads to vascular leakage, with an increased potential for tumor cell metastasis (1, 53) . Pericytes also play a critical role in the development and maintenance of the blood-brain barrier, and pericyte deficiency both increases the permeability of the blood-brain barrier (5, 7, 21) and reduces brain capillary perfusion (7) . Diabetic retinopathy is characterized by excessive vascular permeability in the retina and is caused by continual pericyte loss over time (25) . Finally, high doses of Gleevec, a pharmacological inhibitor of PDGF-B signaling, lead to increased risk of edema and interstitial leakage of fluid (31) . These data led us to hypothesize that reduced PDGF-B signaling may increase vascular permeability and thereby improve insulin delivery to its target cells.
To address this hypothesis, we studied PDGF-B retentiondeficient (PDGF-B ret/ret ) mice. PDGF-B is secreted as a homodimer from endothelial cells, where it is retained on the cell surface by a COOH-terminal heparan-sulfate proteoglycanbinding retention motif (40) . Deletion of this motif in the PDGF-B ret/ret mice leads to decreased retention of PDGF-B and a reduction in PDGF-B signaling (40, 43) . PDGF-B ret/ret mice display a loss of pericyte density, pericyte detachment, and abnormal capillary morphology in the developing brain, kidney, and retina as well as the postnatal kidney and retina (37) .
In the present study, we demonstrate that impaired PDGF-B signaling enhances vascular transendothelial transport in the liver. The resulting elevations in hepatic insulin signaling lead to improved whole body glucose clearance. To metabolically challenge these animals, we bred the Leptin ob (Lep ob ) mutation (56) into the PDGF-B ret/ret background to generate obese PDGF-B retention-deficient mice. Despite an 88% reduction in plasma insulin, the mice had normal glucose levels, reflecting a drastic improvement in insulin action. These phenotypes appear to result from elevated insulin transport and signaling rather than a loss of ␤-cell secretory capacity. To the best of our knowledge, this represents the first study that links reduced PDGF-B signaling to increased insulin action and establishes that hepatic vasculature can be made even more permeable. FITC-dextran leakage. Mice were anesthetized with a 250 mg/kg dose of Avertin. The right jugular was cannulated and injected with 200 ml of 2 mg/ml lysine-fixable FITC-dextran [10 kDa molecular weight (MW); Invitrogen]. The FITC-dextran circulated for 30 min. Frozen 10-m sections were blocked with 5% donkey serum and stained overnight at ϩ4°C with 1:50 rat anti-platelet endothelial cell adhesion molecule-1 (PECAM-1) antibody (BD Pharmingen) to mark the vasculature. Sections were stained with 1:100 Cy3-conjugated donkey anti-rat secondary antibody (Jackson ImmunoResearch). Confocal images were analyzed using Metamorph software in a blinded manner, and FITC-dextran associated with the vasculature was quantified as a signal that colocalized with PECAM-1. Extravascular FITC-dextran intensity was quantified as a signal that did not colocalize with PECAM-1.
RESEARCH DESIGN AND METHODS

Animals
Pericyte coverage immunohistochemistry. Two frozen 10-m sections/animal were blocked with 5% donkey serum containing 1% Triton X-100 and stained overnight at ϩ4°C with 1:50 rat anti-PECAM-1 antibody (as described in FITC-dextran leakage) and 1:100 rabbit anti-desmin antibody (Abcam) to mark HSCs. Sections were stained with anti-rat (above) or 1:100 FITC-conjugated goat anti-rabbit (Jackson ImmunoResearch) secondary antibodies. We imaged three random images per section, totaling six images per animal. Pericyte coverage was calculated as the desmin area divided by the PECAM-1 area per animal as determined by Metamorph.
Transmission electron microscopy of liver sinusoids. Sections were cut and contrasted with 8% uranyl acetate in 50% ethanol for 7 min at room temperature, followed by Reynolds lead citrate for 5 min at room temperature. Images of hepatic sinusoids were taken at ϫ8,800 magnification on a Philips CM120 transmission electron microscope. Sinusoids were scored in a blinded manner as "intact" (fenestrated with a wellformed space of Disse) or "disrupted" (defenestrated with a disorganized, electron-dense space of Disse). Results are presented as intact or disrupted sinusoids as a percentage of total images analyzed per animal.
Insulin signaling Western blots. Mice were given a 5-min portal vein injection of 5 U of insulin to measure insulin receptor-␤ (IR␤) signaling or were injected with 0.1 U/kg insulin via jugular vein for 15 min to measure Akt signaling. Livers were lysed on ice for 30 min in 50 mM HEPES buffer (pH 7.4) containing 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, and 10% glycerol and supplemented with a protease and phosphatase inhibitor cocktail (Roche). Supernatants were collected via centrifugation at 15,000 g for 20 min, and protein concentration was measured by BCA assay.
Total liver homogenates (200 mg for IR␤, 50 mg for Akt) were subjected to SDS-PAGE, transferred to nitrocellulose membrane, and blotted with a mouse anti-phosphotyrosine antibody (1:1,000; Millipore) for IR␤ or a mouse anti-phospho-Akt (Ser 473 ) antibody (1:1,000; Cell Signaling Technology) overnight. To detect total protein, blots were stripped and probed overnight with a rabbit anti-IR␤ antibody (1:1,000; Santa Cruz Biotechnology) or a rabbit anti-Akt antibody (1:1,000; Cell Signaling Technology). ) by the plasma glucose concentration (mg/ml).
Tissues (50 mg) were homogenized in 0.5% perchloric acid and centrifuged for 20 min at 2,000 g. Radioactivity was counted from the initial supernatant (supernatant 1) and the supernatant following Ba(OH) 2 Insulin and glucose tolerance tests and glucose-stimulated insulin secretion from isolated islets. Insulin tolerance tests were performed on nonfasted animals. Blood samples were drawn before insulin injection (Novolin R; Novo Nordisk) and at 5, 15, 30, 60, and 120 min after intraperitoneal injection. Lep ϩ/ϩ mice were given 0.1 U/kg body wt insulin in sterile saline, whereas Lep ob mice were given 20 U/kg body wt. Human plasma insulin was measured using a radioimmunoassay (Millipore).
Glucose tolerance tests were performed on mice fasted overnight. Glucose (2 mg/g body wt in sterile saline) was administered intraperitoneally. Blood samples were drawn before glucose injection and at 15, 30, 60, 120, 240, and 360 min after injection. Plasma C-peptide levels were measured using a radioimmunoassay (Linco-Millipore).
In vitro insulin secretion assays were performed as described previously (42) .
Statistical analysis. Fasting plasma insulin values did not have a normal distribution and were thus analyzed using a Mann-Whitney test. Area under the curve was determined for insulin and glucose tolerance tests and analyzed using unpaired Student t-tests. Curves were not corrected for baseline in these analyses. Individual time points during the insulin and glucose tolerance tests were analyzed by unpaired Student t-tests without adjusting for multiple comparisons; during the insulin tolerance tests, raw (not normalized to time 0) glucose values were used for this analysis. All other studies were analyzed using unpaired Student t-tests.
RESULTS
PDGF-B
ret/ret livers display increased vascular permeability. To study vascular permeability in liver, gastrocnemius muscle, and heart, we carried out intrajugular injection of 10 kDa FITC-dextran. The most striking difference was found in liver, where after only 30 min of circulation, we observed an approximately threefold increase in FITC-dextran accumulation in PDGF-B ret/ret relative to PDGF-B ret/ϩ control mice (Fig. 1,  A-C) . Of the accumulated FITC-dextran, 38% remained associated with the vasculature in control liver compared with only 14% in PDGF-B ret/ret liver, suggesting more rapid diffusion of dextran out of the vascular space in PDGF-deficient mice. We did not observe leakage in skeletal muscle but found increased leakage in PDGF-B ret/ret heart after only 24 h of circulation. PDGF-B is a known mitogen and chemotactic growth factor for liver pericytes, also known as hepatic stellate cells (HSCs) or Ito cells (45) . In addition, PDGF-B induces pericyte recruitment and attachment to endothelial cells in other vascular beds (23) . Pericyte coverage is believed to play an important role in the maintenance of vascular barrier function (44) . Therefore, loss of pericyte coverage induced by the PDGF-B ret/ret mutation may explain the difference in vascular permeability noted in the PDGF-B ret/ret liver. To quantify hepatic pericyte coverage, we performed immunohistological analysis of wild-type and PDGF-B ret/ret liver vasculature and staining for sinusoidal endothelial cells (PECAM-1) and hepatic stellate cells (desmin). Despite the loss of pericytes in numerous other tissues, we did not observe a loss of HSC coverage in PDGF-B ret/ret liver (Fig. 1, D-F) . This implies that PDGF-B deficiency increases hepatic vascular permeability independently of its effects on liver pericyte density.
PDGF-B signaling also contributes to hepatic stellate cell activation (20) . This process is characterized by sinusoidal capillarization, a process by which liver sinusoids become defenestrated and display fibrotic alterations to the space of Disse (22) . Capillarization can prevent the delivery of macromolecules to hepatocytes in models of liver fibrosis, injury, obesity, and aging (34, 38) . Therefore, we analyzed PDGF-B wt/wt and PDGF-B ret/ret sinusoidal ultrastructure by transmission electron microscopy. The majority of PDGF-B ret/ret sinusoids (80%) were intact, as marked by a highly fenestrated endothelium and well-formed space of Disse with numerous hepatocyte microvilli (Fig. 1, H and I) . In contrast, ϳ60% of PDGF-B wt/wt sinusoids displayed some form of disruption, including defenestration and a disordered electron-dense space of Disse (Fig. 1, G and I) . Together, these data suggest that PDGF-B deficiency prevents capillarization-like alterations to the hepatic sinusoidal ultrastructure, thereby enhancing transendothelial transport in the liver.
PDGF-B ret/ret mice display enhanced hepatic insulin signaling and whole body glucose uptake. PDGF-B
ret/ret mice have elevated hepatic sinusoidal transport that appears to result from a reduction in capillarization-like changes to the sinusoidal architecture. Given that the molecular weight of the FITCdextran we used was 10 kDa and that of insulin was ϳ6 kDa, we hypothesized that PDGF-B-deficient sinusoids might be more permissive for insulin delivery to hepatocytes. This would lead to greater downstream insulin signaling. Therefore, we examined phosphorylation of the IR␤ and Akt at 5 and 15 min, respectively, after intraportal injection of insulin. Phosphorylation of both IR␤ and Akt was increased in the livers of PDGF-B ret/ret mice (3-fold increase over wild type for IR␤, 5-fold for Akt; Fig. 2, A and B) .
To evaluate the downstream effects of insulin stimulation, we quantified the mRNA abundance of insulin-regulated genes. Insulin signaling induces the expression of glucokinase, and we observed a twofold elevation in glucokinase mRNA in PDGF-B ret/ret liver (Fig. 2C ). Insulin signaling also suppresses the expression of glucose-6-phosphatase, and accordingly, we observed an 80% reduction in glucose-6-phosphatase mRNA in PDGF-B ret/ret liver (Fig. 2C) . These results support our hypothesis that elevated hepatic vascular permeability increases insulin signaling as a consequence of PDGF-B deficiency.
We next asked whether this increased hepatic insulin signaling could affect hepatic glucose uptake. In hepatocytes, glucose transport is not determined by the abundance of glucose transporters but is largely determined by the capacity of hepatocytes to phosphorylate glucose, i.e., the abundance of glucokinase. Mice were injected intravenously with insulin (0.1 U/kg), glucose, and a 2-[ 14 C]deoxyglucose tracer. After 15 min of circulation, 14 C radioactivity was measured in the liver. Hepatic glucose uptake was increased twofold in PDGF-B ret/ret mice compared with PDGF-B wt/wt mice (Fig. 2D ). This measurement correlates with increased whole body insulin-stimulated glucose clearance in PDGF-B ret/ret mice following an intraperitoneal insulin injection (Fig. 2E) (Fig. 4A) . Despite a severe reduction in fasting plasma insulin and a severe reduction in the insulin secretory response to a glucose challenge (Fig. 4C ), fasting glucose ( Fig.  4B ) and postchallenge glucose (Fig. 4D) were at the normal range of Lep ob . Together, these data show that the loss of PDGF-B function greatly enhances insulin action in vivo, enabling severely obese mice to avoid hyperglycemia despite a very low insulin level.
PDGF-B ret/ret Lep ob mice display intact ␤-cell secretory capacity. A surprising result was the essentially flat insulin response of the PDGF-B
ret/ret Lep ob mice after a glucose challenge (Fig. 4C ). This is a consequence of very rapid insulin clearance (Fig. 3B) , but it may also reflect reduced insulin secretion. To assess ␤-cell secretion in vivo, we quantified C-peptide levels. After a glucose challenge, the PDGF-B ret/ret Lep ob C-peptide area under the curve was reduced by 36% relative to Lep ob controls (Fig. 5A ). The C-peptide/insulin ratio can be used as a surrogate measurement of insulin clearance because C-peptide is released in equimolar amounts to insulin but is cleared from circulation at approximately one-tenth the rate of insulin (48) . The C-peptide/insulin ratio was significantly higher over time in PDGF-B ret/ret Lep ob mice (Fig. 5B) , consistent with the reduced area under the curve of plasma insulin during the insulin tolerance curve (Fig. 3B) .
To directly assess ␤-cell insulin secretory function, we measured glucose-stimulated insulin secretion from isolated islets in vitro. Both insulin secretion in response to high glucose and total cellular insulin content were reduced significantly in islets from PDGF-B ret/ret Lep ob mice (Fig. 5C ). However, when normalized for insulin content, PDGF-B
ret/ret
Lep ob fractional insulin release was not significantly different from control Lep ob islets (Fig. 5D ), indicating that the secretory capacity of PDGF-B ret/ret islets is intact and that the reduced insulin secretion is due to a large reduction in the pool of available insulin in the ␤-cells. The ␤-cell area (Fig. 5E ), islet size (data not shown), and ␤-cell architecture (data not shown) were not significantly different between PDGF-B wt/wt Lep ob and PDGF-B ret/ret Lep ob mice, suggesting that the reduced insulin content results from diminished insulin synthesis in the ␤-cells rather than a loss of ␤-cells.
DISCUSSION
In the present study, we demonstrate that PDGF-B deficiency prevents hepatic capillarization and thereby increases hepatic vascular permeability. This results in increased hepatic insulin signaling, suggesting improved insulin delivery to hepatocytes. In obese mice, this enhanced hepatic insulin signaling partially ameliorates the insulin resistance and hyperinsulinemia normally associated with obesity ( Fig. 6 ) and is associated with a far lower glucose level than one would normally expect in obese mice with low insulin levels.
Unlike muscle, where transendothelial transport is known to be rate limiting for insulin delivery (6, 18) , the liver is considered to be freely permeable to most solutes, and vascular delivery to hepatocytes has not been believed to limit hormone action (34) . Although defenestration and alterations to the perisinusoidal space can impede the delivery of macromolecules to hepatocytes (34, 38) , most studies have focused on cases of advanced cirrhosis and fibrosis. We show that hepatic sinusoidal transendothelial transport can be improved even in animals lacking overt liver fibrosis and that such changes affect whole body insulin and glucose homeostasis.
We were surprised to observe equal HSC coverage of sinusoidal vessels in PDGF-B wt/wt and PDGF-B ret/ret liver. However, in PDGF-B Ϫ/Ϫ embryos, which do not survive to birth, HSCs develop normally in the liver (28) , suggesting that another factor can induce HSC recruitment in the face of reduced hepatic PDGF-B signaling. Multiple growth factors that function in signaling and recruitment of pericytes have been identified (23) , and the identity of the pericyte recruitment factor in the liver remains to be elucidated. Our data imply that PDGF-B controls hepatic sinusoidal function independently of its role in pericyte recruitment in the liver.
One such potential function for PDGF-B involves HSC activation, the process by which normally quiescent HSCs begin synthesizing ECM (45) . HSC activation and the resulting ECM production are classically attributed to transforming growth factor-␤ (TGF␤) signaling (11) . However, hepatic PDGF-B overexpression has more recently been shown to trigger HSC activation and fibrosis independently of TGF␤ (20) . In our study, ϳ60% of PDGF-B wt/wt sinusoids were noticeably altered. These disruptions resembled the sinusoidal changes reported for HSC activation, including loss of endothelial fenestration and accumulation of electron-dense ECMlike material in the space of Disse (45) . In contrast, hepatic sinusoidal architecture was noticeably improved in PDGF-B ret/ret mice. The results of our study provide further evidence that PDGF-B plays an active role in sinusoidal remodeling.
Hepatic steatosis/NAFLD is the most common manifestation of liver insulin resistance, and B6 mice are predisposed to the development of fatty liver, even in the lean state (10) . Ultrastructural changes to the hepatic sinusoids are common in NAFLD (3), and this may explain why reduced PDGF-B signaling actually improves hepatic sinusoidal structure in the B6 background. Indeed, black and tan, tufted mice are resistant to the development of fatty liver, and they display reduced sinusoidal alterations compared with B6 mice (data not shown). These studies suggest that sinusoidal dysfunction plays a role in the development of hepatic insulin resistance.
Our data illustrate that changes in liver transendothelial transport due to loss of PDGF-B retention result in elevated whole body insulin and glucose clearance. This is a unique mechanism for enhancement of insulin sensitivity, because insulin resistance is classically thought to occur through defects in the intracellular insulin-signaling cascade downstream of the insulin receptor. Our findings demonstrate a novel role for PDGF-B in hepatic insulin signaling and maintenance of euglycemia and emphasize that hepatic delivery of insulin is an important step in insulin action.
One of the major observations in the present study is that the loss of PDGF-B retention causes a profound increase in insulin sensitivity in PDGF-B ret/ret Lep ob mice. This improvement in insulin sensitivity prevents the expected obesity-induced insulin resistance and hyperinsulinemia of PDGF-B ret/ret Lep ob mice. The mice maintain the same abnormal fasting glucose values as the Lep ob controls and similar glucose tolerance despite drastically reduced fasting insulin levels and reduced glucose-stimulated insulin secretion. The ␤-cell secretory machinery remains functional upon PDGF-B deficiency, as demonstrated by normal in vitro fractional insulin secretion from isolated islets. The observed decrease in insulin secretion is most likely due to reduced insulin demand. Improvements in Fig. 6 . Reduced PDGF-B signaling improves hepatic vascular delivery of insulin and enhances whole body insulin and glucose homeostasis. In C57BL/6J mice, normal PDGF-B retention and signaling leads to ultrastructural changes to the hepatic sinusoids, including loss of fenestration and extracellular matrix-like deposition in the SD. These alterations impede the normally rapid delivery of insulin to hepatocytes. Loss of PDGF-B retention leads to a reduction in these alterations, resulting in enhanced hepatic insulin delivery and signaling. The resulting upregulation of glucokinase and suppression of glucose-6-phosphatase should trigger elevated hepatic glucose flux while reducing glucose output into circulation, resulting in better maintenance of glucose homeostasis. In the obese state, this enhanced glycemic control likely triggers feedback mechanisms that signal to the ␤-cells to reduce insulin secretion, thereby alleviating the hyperinsulinemia typically associated with obesity. ECM, extracellular matrix.
insulin sensitivity are often accompanied by corresponding decreases in insulin secretion and ␤-cell insulin content (16) .
The present study provides new insights into the effect of imatinib mesylate (Gleevec) on diabetes. Imatinib mesylate inhibits several receptor tyrosine kinases, including PDGFR␤ (13) . Imatinib mesylate lowers fasting blood glucose levels in diabetic patients treated for chronic myeloid leukemia (2, 12, 13, 49) . Treatment of db/db mice with imatinib mesylate improves insulin sensitivity and decreases in vivo insulin secretion in response to a glucose challenge (26) . It is possible that the observed increase in insulin sensitivity may involve PDGFR␤ inhibition and subsequent effects on hepatic sinusoidal structure. Sinusoidal fibrosis is reduced upon imatinib mesylate treatment (54) . This suggests that further investigation into the effects of imatinib mesylate and other PDGFR␤ inhibitors on HSC function might uncover new avenues, leading to the treatment of insulin resistance and type 2 diabetes.
Our results also provide a basis for further study into the mechanisms underlying the action of Sorcs1, a PDGF-Bbinding protein (29) . Several studies have suggested that Sorcs1 expression modulates diabetes in both rodents and humans (19, 24, 41) , although its mechanism of action is not clear. The present study demonstrates that modulation of PDGF-B levels can affect insulin action, and Sorcs1 binding to PDGF-B could potentially affect PDGF-B availability, clearance, or function.
In conclusion, this study shows that loss of PDGF-B enhances hepatic insulin action, resulting in improved glucose tolerance. This enhanced glycemic control reduces the need for excessive insulin secretion, alleviating the hyperinsulinemic state normally seen in obese animals. Most importantly, our work reveals a novel role for PDGF-B in hepatic insulin delivery and supports the concept that insulin access to its target tissues is a vital part of insulin sensitivity.
